Efficacy and Safety of Subcutaneous Administration of Fremanezumab for Migraine

Study Title

Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine

Teva Identifier

TV48125-CNS-30051 | 2015-004550-18

ClinicalTrials.gov Identifier

NCT02638103

Study Status

Completed

Trial Condition(s)

Migraine

Interventions

Drug: Fremanezumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Click for participation criteria and map of study locations

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 70 Years

Trial Duration

February 26, 2016 - December 8, 2018

Phase

Phase 3

Study Type

Interventional